Cargando…

Effective Treatment of NSCLC with Surgery After Nivolumab Combined with Chemotherapy: A Case Report and Brief Review of the Literature

INTRODUCTION: Immuno checkpoint inhibitors (ICIs) including anti-PD-L1 antibody have shown certain therapeutic effects on various cancer types. Here, we reported a case of the patient with resectable non-small cell lung cancer (NSCLC) showing a complete response to nivolumab combined with chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Liangchen, Li, Luzhen, Chen, Ting, Fang, Cantu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779284/ https://www.ncbi.nlm.nih.gov/pubmed/33408481 http://dx.doi.org/10.2147/OTT.S266155

Ejemplares similares

Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy
por: Li, Luzhen, et al.
Publicado: (2022)

Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
por: Wang, Yang, et al.
Publicado: (2021)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
por: Remon, Jordi, et al.
Publicado: (2019)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Stereotaktische Radiotherapie plus Nivolumab bei NSCLC
por: Krug, David, et al.
Publicado: (2023)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
por: Lee, Alexandria T M, et al.
Publicado: (2023)

Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery
por: Dai, Peilin, et al.
Publicado: (2022)

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
por: Camidge, D. Ross, et al.
Publicado: (2021)

Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases
por: Wong, Philip, et al.
Publicado: (2023)

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer
por: Derks, Sarah, et al.
Publicado: (2022)

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis
por: Vansteenkiste, Johan
Publicado: (2017)

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
por: Passiglia, Francesco, et al.
Publicado: (2019)

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Efficacy and safety of salvage radiotherapy combined with endocrine therapy in patients with biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis of randomized controlled trials
por: Liang, Zhanpeng, et al.
Publicado: (2023)

Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature
por: Song, Lei, et al.
Publicado: (2020)

Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
por: Cui, Pengfei, et al.
Publicado: (2020)

A single-center randomized controlled study of intraperitoneal hyperthermic chemoperfusion in combination of recombinant human tumor necrosis factor (TNF) in treatment of malignant ascites caused by advanced abdominal cancers
por: Wu, Lexia, et al.
Publicado: (2022)

Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
por: Watanabe, Hayato, et al.
Publicado: (2021)

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
por: Okeya, Komugi, et al.
Publicado: (2020)

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
por: Reuss, Joshua E., et al.
Publicado: (2016)

Brief report: risk stratification following curative therapy for stage I NSCLC
por: Butts, Emily, et al.
Publicado: (2023)

Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations
por: Sato, Miyuki, et al.
Publicado: (2019)

Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC
por: Carbone, Federico, et al.
Publicado: (2021)

Diagnosis and treatment of HS after endoscopic thyroid surgery: case report and brief literature review
por: Deng, Yuqing, et al.
Publicado: (2023)

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial
por: Clarke, Jeffrey M., et al.
Publicado: (2022)

Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
por: Kunimatsu, Yusuke, et al.
Publicado: (2023)

Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research
por: Gassmann, Dimitri, et al.
Publicado: (2018)

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)
por: Hellmann, Matthew, et al.
Publicado: (2015)

Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report
por: Liu, Shilan, et al.
Publicado: (2022)

Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
por: Melian, Marcos, et al.
Publicado: (2018)

Nivolumab in the treatment of malignant melanoma: review of the literature
por: Mashima, Emi, et al.
Publicado: (2015)

Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

Gastric adenocarcinoma is concurrent with metastatic neuroendocrine cancer treated with nivolumab and chemotherapy: A case report
por: Yan, Bing, et al.
Publicado: (2018)

Delayed suprachoroidal hemorrhage after cataract surgery: A case report and brief review of literature
por: Song, Wei, et al.
Publicado: (2018)

Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly
por: Wu, Chunrong, et al.
Publicado: (2018)

Efficacy of Mecobalamin Tablets Combined with Troxerutin in the Treatment of NSCLC Chemotherapy-Induced Peripheral Neuropathy
por: Li, Yang, et al.
Publicado: (2022)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
por: Andric, Zoran, et al.
Publicado: (2023)

Pericardial effusion under nivolumab: case-reports and review of the literature
por: Anastasia, Saade, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5341v7sn0assrej6ut4hhufmo7